Xiamen Spacegen Co., Ltd. (2025)

21/11/2025

The National Comprehensive Cancer Network (NCCN) released the latest "Clinical Practice Guidelines for Non-Small Cell Lung Cancer (NSCLC) Version 1.2026" on November 6, 2025. Compared to the 8th edition from 2025, it has undergone several significant updates. The new version of the guideline has achieved a "disruptive" update in the field of biomarker testing—from the definition of terms to the scope of testing, from technical paths to clinical linkage, it has comprehensively propelled the precise treatment of lung cancer into a new era of "full-spectrum testing."
For patients, genetic testing is no longer an "optional add-on," but the "key first step" that determines the treatment direction and survival time. For clinicians, the guideline provides a standardized testing path, avoiding treatment delays caused by incomplete testing and inappropriate timing. With the deepening understanding of tumor biology, in the future, genetic testing will not only identify single mutations but also comprehensively assess the molecular characteristics of tumors, including co-mutation situations, tumor heterogeneity, and evolutionary mechanisms, etc. Multidisciplinary collaboration is particularly important in the precise diagnosis and treatment of lung cancer. Facing the increasingly complex and variable biological characteristics of tumors, a single treatment approach is no longer sufficient to meet the challenges. Therefore, future precise treatment will be a cross-disciplinary collaborative effort, forming a more comprehensive and precise treatment system.

31/10/2025

Ovarian endometrioid cancer (OEC) is an epithelial malignant tumor of the o***y that exhibits a pathological morphology similar to endometrioid cancer of the endometrium. Its incidence rate ranks second only to high-grade serous cancer of the o***y, accounting for approximately 10% of all epithelial malignant tumors of the o***y. Common molecular mutations in OEC include those of the CTNNB1 and PTEN genes, as well as microsatellite instability (MSI). Other observed mutations are dMMR or POLE (15%), HRD (19%), BRCA1/2 mutations (6%), and PIK3CA mutations (31%).

Despite differences in the proportion of TCGA molecular subtypes and pathological features between ovarian endometrioid cancer and endometrial endometrioid cancer, the prognostic value of TCGA molecular subtypes is similar in both cancers. The extension of endometrial molecular classification to ovarian endometrioid cancer represents not only a technical advancement but also a paradigm shift in diagnosis and treatment. It moves our focus from the "location of the tumor" to the "molecular characteristics of the tumor," and from "uniform treatment" to "personalized treatment." For patients with OEC, this translates to increased hope for survival: early-stage patients can avoid overtreatment, advanced-stage patients can find precise treatment options, and young patients can maintain their fertility. For clinicians, this means a clearer diagnostic and treatment pathway, with each treatment decision backed by "molecular evidence."

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=480&CateID=109&wb=3

31/10/2025

When discussing melanoma, it is often referred to as the "king of skin cancers." It is highly deceptive in its early stages, challenging to treat in advanced stages, and the risk of recurrence looms like a sword of Damocles over patients' heads. Traditional monitoring methods, such as imaging exams, frequently fail to detect abnormalities until the tumor has progressed to a certain stage, potentially narrowing the window for effective treatment.

Nevertheless, the advent of "liquid biopsy" technology, which involves the detection of circulating tumor DNA (ctDNA), is revolutionizing the diagnosis and treatment of melanoma. For patients with melanoma, the importance of ctDNA detection is twofold: it is crucial for monitoring minimal residual disease (MRD) in the early postoperative period and for assessing treatment efficacy in advanced stages. "Recurrence" is the root of fear, but "early detection" is the key to conquering it. The advent of ctDNA detection has made it possible to "anticipate recurrence," "monitor therapeutic effects in real-time," and "accurately stratify risks," offering new hope to patients.

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=479&CateID=109&wb=3

15/10/2025

On October 11, 2025, according to official information released by the National Medical Products Administration (NMPA), Sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate (ADC) independently developed by Kelun Biotech, has been granted approval for a new indication, offering an additional therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) in China. The newly approved indication is for the treatment of adult patients with locally advanced or metastatic NSCLC harboring epidermal growth factor receptor (EGFR) mutations who have experienced disease progression following prior therapy with EGFR tyrosine kinase inhibitors (EGFR-TKIs).

This is the third important indication approved by Sacituzumab in China after the back-line treatment for triple-negative breast cancer and specific non-small cell lung cancer, marking a further expansion of the application domain of this innovative domestic ADC drug in tumor treatment.This approval of the new indication provides a powerful alternative to chemotherapy for patients with EGFR mutant NSCLC after resistance to targeted drugs, and is expected to change the treatment pattern in this field and bring hope for the survival of more patients.

Click to read: http://sspacegen.com/newsinfo.aspx?newsID=477&CateID=109&wb=3

14/10/2025

What impact does HER2 status have on the treatment of gastric cancer? Traditionally, gastric cancer refers to an epithelial-derived malignant tumor that originates in the stomach. According to aggregated data from 2022, gastric cancer is the fifth most common malignant tumor in terms of both incidence and mortality worldwide, with an incidence rate of approximately 970,000 per year and a mortality rate of about 660,000 per year. Human epidermal growth factor receptor 2 (HER2) is a common and important target in gastric cancer. This article explores the gene characteristics that may affect tumor progression and treatment response in HER2-positive and HER2-negative gastric cancer patients, thereby providing new ideas and methods for personalized treatment of gastric cancer.

💡Click to read: http://sspacegen.com/newsinfo.aspx?newsID=476&CateID=109&wb=3

09/10/2025

Did you know? There is a "genetic cancer syndrome" that not only causes a family to successively suffer from colorectal cancer, but also makes women face a 60% risk of endometrial cancer and a 10% risk of ovarian cancer between the ages of 30 and 50. It is called Lynch syndrome, an often overlooked but potentially life-changing "invisible killer" that can be addressed through scientific means. What is Lynch syndrome?

Lynch syndrome is a hereditary cancer syndrome caused by mutations in mismatch repair genes (MMR), which leads to the failure of the DNA repair system, accumulation of cell mutations, and a sharply increased risk of cancer.
(1) Women need to be most vigilant: the risk of endometrial cancer (EC) is 40-60%, and the risk of ovarian cancer (OC) is 8-10%.
(2) Early onset of the disease: It occurs 10 to 20 years earlier than in the general population, and some may develop cancer as early as age 30.
(3) Family clustering: Several generations within a family may be affected, especially with colorectal cancer, endometrial cancer, and ovarian cancer.

Three sentences for every Lynch syndrome female.
（1）You are not destined to get cancer – scientific means can significantly reduce the risk.
(2) You are not alone in this fight - the genetic counseling clinic, gynecological oncology department, and psychological support are all by your side.
(3) You are not passively waiting - starting from today, actively monitor, actively consult, and actively make decisions.

29/09/2025

🎯MRD stands for Molecular Residual Disease testing, which refers to the small amount of cancer cells remaining in the body after cancer treatment. Traditional imaging or laboratory methods cannot detect it early, but through MRD liquid biopsy, cancer-derived molecular abnormalities can be identified, allowing for earlier intervention plans to be implemented.

🧬The main functions of MRD detection are prognosis prediction, recurrence risk assessment, and therapeutic efficacy monitoring. It is widely applied in various types of cancer, including lung cancer, colorectal cancer, breast cancer, esophageal cancer, liver cancer, gastric cancer, bladder cancer, and pancreatic cancer.

🔬SpaceGen now offers two technical routes. One is a fixed-panel test based on plasma ctDNA, which can detect 194 genes in four types of cancer including lung cancer, colorectal cancer, gastric cancer and liver cancer in one go. In addition, personalized panel customization can also be provided as needed.

📩 For the complete product catalog or to explore more cooperation opportunities, feel free to contact us at spacegen@ispacegen.com.

🌍 Welcome to visit the official website of SpaceGen for more information: sspacegen.com

, ,

28/09/2025

《Revisiting the Molecular Classification of Endometrial Cancer》

The TCGA molecular typing of endometrial cancer integrates genomic, transcriptomic, proteomic, gene copy number, and methylation data, classifying EC into four subtypes: POLE ultramutated (POLEmut), microsatellite instability-high (MSI-H), copy number low (CNL), and copy number high (CNH). Since then, many scholars have simplified the methodology and optimized the process of EC molecular typing, proposing the TransPORTEC and ProMisE molecular typing strategies. Molecular typing has gradually gained an increasingly important position. Nowadays, molecular typing has been recommended by domestic and international guidelines and consensus, and the new FIGO 2023 staging system has also incorporated molecular features .

Although molecular typing of endometrial cancer has been recommended by multiple guidelines and consensus, it is undeniable that there are still many problems with the current molecular typing. There are many blank areas and issues worth exploring in the clinical application stage, such as how molecular typing can guide the selection of surgical scope; whether immune and targeted drugs based on molecular typing results can be recommended as first-line options for fertility preservation or clinical adjuvant therapy, etc. With the continuous development of molecular biology technology and the conduct of prospective clinical research trials, the precise diagnosis and treatment of endometrial cancer are expected to be further improved.

Original Article Express：www.sspacegen.com

10/09/2025

Over the past 40 years, small cell lung cancer (SCLC) has been a clinical "hard nut to crack", with almost no options left after chemotherapy resistance.

Now, a major review in Nature Cancer brings six breakthrough directions, offering the first glimpse of the possibility of being besieged by "curative-level" therapies for this "incurable disease". SCLC has finally entered the "treatment explosion" era!

The treatment of SCLC is shifting from "laboratory to clinical" to "bedside back to laboratory" reverse translation: circulating clinical observations, deep omics, tissue banks and rapid autopsy results back to the laboratory to drive hypothesis validation and target discovery; while using surface omics, ADC/TCE new drugs, rational combination regimens, limiting phenotypic plasticity and epigenetic intervention to counter heterogeneity and resistance; moving the battle line forward through smoking cessation, early screening and circulating biomarkers; and solving the obstacles of age, comorbidities and economic accessibility in the real world to truly implement innovative therapies.

Original Article Express：www.sspacegen.com

08/09/2025

Have you ever wondered why cancer seems to be particularly prevalent in some families? In fact, about 5% to 10% of tumors are closely related to genetic factors. With the development of genetic testing technology, we can now uncover the secrets hidden in DNA. Genetic testing is not fortune-telling but a science. It gives us an unprecedented ability to predict risks and proactively manage our health. Understanding the genetic susceptibility to gynecological tumors, through scientific genetic testing and professional genetic counseling, can help high-risk individuals (whether patients or healthy carriers) detect risks earlier, treat tumors more precisely, prevent related cancers more effectively, and guide scientific family planning. This is not only an active management of personal health but also a responsibility towards the health of family members. If you meet the risk factors mentioned in the text, it is recommended to consult a doctor or genetic counselor to assess the necessity of genetic susceptibility testing.

Original Article Express：www.sspacegen.com

04/09/2025

Although the incidence and mortality rates of leukemia have decreased significantly worldwide over the past 50 years, leukemia remains a global health challenge, being the 13th most common cancer and the 10th leading cause of cancer-related deaths globally.

Each year, hundreds of thousands are affected, highlighting the urgent need for awareness, early detection, and innovative treatments.

At spacegen, we’re working to change the landscape of Leukemia treatment through precision oncology. By analyzing each patient’s unique genetic and molecular profile, we help clinicians personalize treatment plans, ensuring the best possible care for Leukemia patients.

This , let’s come together to raise awareness, support those affected, and continue pushing for better diagnostic tools and treatments.

03/09/2025

On August 22, 2025, the National Medical Products Administration (NMPA) of China approved the marketing of datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo, for the treatment of adult patients with unresectable or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer who have received endocrine therapy and at least one line of advanced chemotherapy. This approval offers a new option for patients with drug-resistant disease in this subtype.

This approval is based on the results of the global Phase III TROPION-Breast01 study: Compared with chemotherapy, datopotamab deruxtecan significantly reduced the risk of disease progression or death by 37%, and the median progression-free survival (mPFS) was extended to 6.9 months (4.9 months in the chemotherapy group). Data from the Chinese subgroup showed that the median PFS reached 8.1 months, nearly twice that of the chemotherapy group (4.2 months). HR+/HER2- breast cancer accounts for 70% of all breast cancers. Patients often face drug resistance after endocrine therapy and chemotherapy. As Daiichi Sankyo's second ADC drug approved in China after Enhertu for breast cancer, datopotamab deruxtecan will fill the unmet clinical needs.

Original Article Express：www.sspacegen.com

Xiamen Spacegen Co., Ltd.

21/11/2025

31/10/2025

31/10/2025

15/10/2025

14/10/2025

09/10/2025

29/09/2025

28/09/2025

10/09/2025

08/09/2025

04/09/2025

03/09/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share